Personalized Medicine Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Global “Personalized Medicine Market” forecast 2020-2024 is a historical overview and in-depth study on the present and upcoming market of the Personalized Medicine industry. The report represents a basic overview of the Personalized Medicine market size, share, and competitor segment with a basic introduction of manufactures, geographical regions, product types, and applications. This report gives a historical overview of the Personalized Medicine market trends, growth, revenue, capacity, cost structure, and key driver’s analysis.

About Personalized Medicine:

Individualized medication, medication “vary from person to person” , give full consideration to each patient’s genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effective and economic drug treatment.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/14684359

Personalized Medicine Market Segment by Manufacturers, this report covers:

● Abbott Laboratories ● Agilent Technologies ● Amgen ● Astellas Pharma ● Astrazeneca ● Bayer AG ● Celgene Corporation ● Glaxosmithkline Plc ● Illumina ● Johnson and Johnson ● Laboratory Corporation ● Merck ● Novartis AG ● Roche Holding AG ● Siemens AG ● Takeda Pharmaceutical Company Limited

Market Segment by Regions, regional analysis covers:

● North America (United States, Canada and Mexico) ● Europe (Germany, France, UK, Russia and Italy) ● Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ● South America (Brazil, Argentina, Colombia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

● Personalized Medicine Diagnostics ● Personalized Medical Care ● Personalized Medicine Therapeutics ● Personalized Nutrition and Wellness

Market Segment by Applications, can be divided into:

● Oncology ● Central Nervous System (CNS) ● Immunology ● Respiratory ● Other Applications ● Personalized MedicinePersonalized Medicine

To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/14684359

Scope of this report:

● The global Personalized Medicine market is expected to reach significant USD by the end of 2024. ● The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. ● North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine. ● Europe also play important roles in global market, with market size of significant USD in 2019. ● This report studies the Personalized Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine market by product type and applications/end industries.

The content of the study subjects includes a total of 15 chapters:

● Chapter 1, to describe Personalized Medicine product scope, market overview, market opportunities, market driving force and market

Read more

First-Ever Treatment Shown to Reverse Alzheimer’s Earns NeuroEM Therapeutics FDA Breakthrough Device Status

The FDA is expediting a revolutionary clinical-stage head device to beat back Alzheimer’s disease at home

NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005376/en/

Woman pictured wearing NeuroEM Therapeutics’ bioengineered MemorEM™ cap and arm control box. This revolutionary head device has earned FDA Breakthrough Device designation, having demonstrated in a pilot study that it can reverse Alzheimer’s disease. This woman’s participation in the study resulted in her regaining the equivalent of 12 months of memory. (Photo: Business Wire)

“No other drug or device has received this highest FDA designation to accelerate a treatment for Alzheimer’s disease,” said Dr. Robert Matthews, PhD, CEO of NeuroEM Therapeutics. “No other treatment has demonstrated the clinical results we have thus far, to not only slow but in fact reverse the progressive, debilitating loss of memory caused by this devastating brain disease.”

The FDA has given Breakthrough status to over 300 devices and over 100 drugs, but none to a therapeutic for Alzheimer’s disease – until now. NeuroEM’s head device (MemorEMTM) is the first-ever Alzheimer’s treatment (device or drug) to receive FDA Breakthrough status. The FDA program is designed to expedite the development and review process of new technology for patients with life-threatening or irreversibly debilitating conditions, such as Alzheimer’s Disease.

  • NeuroEM’s novel, proprietary technology, called Transcranial Electromagnetic Treatment (TEMT), achieves what other treatments for AD have not. In fact, no other therapy comes close to MemorEM’s remarkable results, made possible by its unique modes of action.

  • In just two months of daily use, the MemorEM restored on average the equivalent of 12 months of memory for 7 of 8 participants in its pilot study, none of whom experienced adverse side effects.

  • Treatment is easy, comfortable and safe. A patient wears what appears to be a simple cap that belies the complex biomedical engineering within it. The device is worn twice a day in home for an hour at a time, and its design allows the patient to move around home as usual.

NeuroEM has pioneered TEMT to successfully penetrate the skull to reach vital nerve cells in the brain called neurons. NeuroEM’s revolutionary TEMT technology works by breaking up small aggregates (oligomers) of two toxic proteins, called β-amyloid and tau, that are made inside the brain’s neurons during the Alzheimer’s disease process. These two toxic oligomers appear to be the root cause of Alzheimer’s disease by wreaking havoc on vital functions within neurons – especially in brain areas involved in memory. The electromagnetic waves emanating from multiple emitters within NeuroEM’s MemorEM head device easily penetrate the human brain and gently disassociate the toxic oligomers inside neurons resulting in a reversal of Alzheimer’s memory impairment in key

Read more

DVIDS – News – Aerospace Medicine Implements Return to Flight Duty Status Guidelines for Aircrew Affected by COVID-19


As much of the military works to maintain readiness in the face of the Coronavirus (COVID-19), Aerospace medicine providers are working to implement a guideline with a set of return to flight duty status protocols. The guideline describes how Service members who are in a ‘down’ flight status may safely return to an ‘up’ flight status after close contact or contracting COVID-19.

These protocols were developed in response to Navy and Marine Corps Aerospace Medicine COVID-19 cases and are promulgated to synchronize the community’s approach to medical evaluation when returning aircrew to flight duty status. The protocols within the guideline are reviewed biweekly to incorporate the most updated national guidelines and current published research.

“The return to flight duty status guideline is critical to maintaining operational readiness amongst our aircrew and return them safely to the cockpit,” said CDR Allen Hoffman, Branch Head of Aerospace Medicine Programs at the U.S. Navy Bureau of Medicine and Surgery.

These protocols provide a basic framework for our squadron flight surgeons who will also use their sound clinical judgement when comprehensively evaluating each patient. The guideline details step by step how aircrew can return to flight duty status if they are determined to have contracted the virus or had close contact with someone who has contracted COVID-19.

“There are important clinical criteria for aerospace providers to follow if aircrew contracts COVID-19. For example, it is imperative that the provider follow-up with the infected individual once they have recovered to determine if they have optimal respiratory function and returned to a the physical fitness level necessary to safely operate in the flight environment,” said CDR Hoffman.

To know whether affected aircrew are able to safely operate an aircraft, they must meet set physical standards during a series of tests, including a physical exercise tolerance test. Some of those tests help determine if there are still any remaining functionally limiting damage caused by COVID-19.

“The medical evaluation and information in the guidance will ensure our aircrew are ready to fly after contracting COVID-19. Their health and safety is our first and foremost mission in supporting the warfighter,” said CDR Hoffman.

The official guidance will be published in the Naval Aerospace Medical Institute’s, Aerospace Reference and Waiver Guide by mid-November.

Navy Medicine is a global health care network of 63,000 personnel that provide health care support to the U.S. Navy, Marine Corps, their families and veterans in high operational tempo environments, at expeditionary medical facilities, medical treatment facilities, hospitals, clinics, hospital ships and research units around the world.

For more information about Navy Medicine, visit www.med.navy.mil





Date Taken: 10.20.2020
Date Posted: 10.20.2020 15:19
Story ID: 381341
Location: FALLS CHURCH, VA, US 




Web Views: 3
Downloads: 0
Podcast Hits: 0


PUBLIC DOMAIN  

Source Article

Read more
  • Partner links